CRM Executive

UK (Hybrid)

Salary Not AvailableMid LevelFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Salesforce Marketing Cloud powered CRM and email program owner driving lifecycle engagement, LTV and compliance using data, tests and personalization.

  • Own targeted email campaigns and daily post campaign analysis to lift response and revenue.
  • Lead cross-functional briefs with design, web, and data to keep communications sharp and compliant.
  • Apply test and learn to improve engagement and lifetime value through automation and Einstein personalization.

Job Description

Responsibilities

  • Work within Salesforce Marketing Cloud application to plan, build and deliver targeted email campaigns against business and department objectives.
  • Regular briefing of internal design team and web team and managing these relationships.
  • Copywriting using best practice direct marketing techniques in order to maximise response.
  • Provide comprehensive daily and post campaign analysis reports of all activity.
  • Use and develop current marketing practices for in-house data, such as marketing automation to drive efficiency and increase Lifetime Value.
  • Continual test and learn focus in order to maintain engagement and response from customer base.
  • Full exploitation of Marketing Cloud Personalisation and Einstein applications to maximise efficiency of our CRM activity
  • Monitoring competitor activity and reporting back to wider team
  • Monitoring Trustpilot and other web-based customer feedback apps
  • Ensure standards are monitored for following best practice, data quality management and compliance with statutory regulations such as GDPR.

Requirements

  • Previous experience of working in a CRM/database marketing role, with email marketing campaigns. This is a great chance to develop and learn !
  • Experience using Salesforce Marketing Cloud or similar platform.
  • Inquisitive marketer who uses date to inform and make commercial decisions
  • Advanced Microsoft Excel
  • Analytical mindset – Test and learn mentality, with great attention to detail
  • Copywriting skill
  • Some basic experience of writing creative briefs. This is preferable but not essential
  • HTML knowledge preferable but not essential

Preferred

  • HTML knowledge preferable but not essential
  • Some basic experience of writing creative briefs. This is preferable but not essential
Vax logo

Vax

4.5 Glassdoor

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.

Founded in 2013
San Carlos, California, USA
506 employees
94% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
18.3K
Traffic Source Mix
Search
36.1%
Direct
45.6%
Referral
8.8%
Social
8.2%
Paid
1.4%

Headcount Trend

Current headcount: ~508

Funding

Total Funding
$4.5B
Last Raise
$632.5M
Post IPO Equity, 2 months ago

Funding History

  • Jan 2026
    Post IPO Equity • $632.5M
  • Sep 2024
    Post IPO Equity • $1.5B
  • Jan 2024
    Post IPO Equity • $862.5M

Recent News